229P - Liquid biopsy based on circulating tumour cells (CTC) detection is a diagnostic and prognostic marker in patients with pancreatic solid tumours

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Pancreatic Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Paul Basile
Citation Annals of Oncology (2014) 25 (suppl_4): iv58-iv84. 10.1093/annonc/mdu326
Authors P. Basile1, D. Sefrioui2, F. Blanchard3, S. Lecleire4, F. Clatot5, J. Sabourin3, P. Michel1, F. Di Fiore1
  • 1Digestive Oncology Unit, CHU Hôpitaux de Rouen-Charles Nicolle, 76031 - Rouen/FR
  • 2Digestive Oncology Unit, C.H.U. Charles Nicolle, FR-76000 - Rouen/FR
  • 3Department Of Pathology, C.H.U. Charles Nicolle, FR-76000 - Rouen/FR
  • 4Digestive Endoscopy Unit, C.H.U. Charles Nicolle, FR-76000 - Rouen/FR
  • 5Medical Oncology Department, Centre Henri Becquerel, 76000 - Rouen/FR



The pancreatic cytology by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is considered as thestandard procedure for the diagnostic of pancreatic tumour. We recently showed that detection of circulating tumour cells (CTC) hada diagnostic accuracy of 70% for pancreatic adenocarcinoma (Am J Gastroenterol 2013;108:152-155). The aim of the study was toevaluate both diagnostic and prognostic impact of CTC detection in an extended series of patients referred for a EUS-FNA for apancreatic solid tumour.


It was a single center study including all consecutive patients referred from 01/2011 to 07/2013 for a EUSFNAprocedure in a context of pancreatic solid mass. EUS-FNA was performed with a 22 gauge needle and analysed by twopathologists. A 10 ml peripheral blood sample was collected in each patient before the EUS-FNA procedure. Samples were filteredusing the ScreencellsCyto method®, stained with Giemsa and analyzed by a cytologist blinded to clinical data and FNA results. The CTC detection was positive according to the presence of the following parameters: nuclear diameter > 7m, anisocytosis, membraneirregularities, presence of a large nucleolus.


A total of 69 patients were included. Amon them, 57 (83%) have a confirmed pancreatic tumours corresponding to 47primitive adenocarcinoma, 4 others primitive tumours and 6 metastatic lesions. The sensitivity and the specificity of EUS-FNA was83% and 100%, respectively. CTC were positive in 36/69 (52%) patients. The sensitivity and specificity of CTC was respectively64.4% and 73.3% in patients with pancreatic cancer and 64.1% and 81.8% in patients with all types of cancer. The presence of CTCwas significantly associated with the diagnostic of cancer (p = 0.01) and with the presence of distant metastases (p = 0.004). In contrast,tumour size, arterial involvement and CA19-9 serum level were not associated with CTC. The 18 months survival rate wassignificantly lower in patients with positive CTC as compared to those without detectable CTC (33 vs 44%, p = 0.03).


Ours results highlighted that liquid biopsy based on circulating tumour cells (CTC) detection may be a diagnosticand prognostic marker in patients with pancreatic solid tumours.


All authors have declared no conflicts of interest.